

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 OCTOBER 2015 – ERRATA

(1) This Erratum corrects the entry for Somatropin in the 1 October 2015 Schedule:

The following items are incorrectly shown as new additions to the listing for Somatropin under the Growth Hormone Program. *Omnitrope Surepal 5* and *Omnitrope Surepal 10* are not available on the PBS from 1 October 2015.

10507B	SOMATROPIN , somatropin 15 international units (5 mg/1.5 mL) injection, 1 x 1.5 mL cartridge (<i>Omnitrope Surepal 5</i>)
10512G	SOMATROPIN , somatropin 15 international units (5 mg/1.5 mL) injection, 1 x 1.5 mL cartridge (<i>Omnitrope Surepal 5</i>)
10518N	SOMATROPIN , somatropin 15 international units (5 mg/1.5 mL) injection, 1 x 1.5 mL cartridge (<i>Omnitrope Surepal 5</i>)
10506Y	SOMATROPIN , somatropin 30 international units (10 mg/1.5 mL) injection, 1 x 1.5 mL cartridge (<i>Omnitrope Surepal 10</i>)
10514J	SOMATROPIN , somatropin 30 international units (10 mg/1.5 mL) injection, 1 x 1.5 mL cartridge (<i>Omnitrope Surepal 10</i>)
10519P	SOMATROPIN , somatropin 30 international units (10 mg/1.5 mL) injection, 1 x 1.5 mL cartridge (<i>Omnitrope Surepal 10</i>)

(2) This Erratum corrects the entry for **Olanzapine** in the 1 October 2015 Schedule.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note was omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

Note

Shared Care Model:

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

(3) This Erratum corrects the entry for **Tocilizumab** in the 1 October 2015 Schedule.

All notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.